Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute.
-
Results from a clinical trial suggest that 177 Lu-Dotatate may soon be a new treatment option for some patients with advanced neuroendocrine tumors.
-
In a clinical trial involving patients with metastatic cancer, administration of zoledronic acid every 12 weeks was as effective at preventing skeletal-related events caused by bone metastases as administration every 4 weeks.
-
A new study by The Cancer Genome Atlas Research Network could help classify esophageal cancers according to their genetic and molecular alterations and identify potential new treatment options.
-
The consumption of cigarettes, small cigars, and chewing tobacco has declined over the past 15 years, according to a new study. These declines were partially offset by a rise in consumption of large cigars, pipe tobacco, and snuff.
-
NCI’s Dr. Mark Parascandola answers questions about The Economics of Tobacco and Tobacco Control, the latest in a series of monographs on tobacco use and tobacco control, which was co-written with the World Health Organization.
-
The targeted cancer therapy ibrutinib can effectively treat the symptoms of chronic graft-versus-host disease, a common and serious complication of allogeneic stem cell transplants, findings from a small clinical trial show.
-
The FDA has approved rucaparib for women with BRCA-positive advanced ovarian cancer based on findings from two small clinical trials showing that it shrank tumors.
-
Researchers have found that duloxetine (Cymbalta®), a drug most commonly used to treat depression, may also reduce joint pain caused by aromatase inhibitors in some women being treated for early-stage breast cancer.
-
Researchers have created a long-sought-after mouse model for an aggressive form of acute lymphoblastic leukemia that occurs commonly in infants and that the researchers believe can accelerate the development of new therapies for the disease.
-
Two new targeted therapies have shown promise in patients with gastrointestinal stromal tumors (GIST) that have developed resistance to standard therapies.